Biotech investors are not generalists. They read your endpoints, your p-values, and your runway math before they read your press release. We build the communication systems that keep specialist life sciences VCs and public biotech analysts confident across years of non-revenue R&D, not just during the good quarters.
The Problem
Trial Readouts Are Treated as One-Off Events, Not Planned Communications
Most biotech teams write the positive-outcome press release and hope for the best. They don't draft the negative-outcome version, the partial-response version, or the ambiguous-endpoint version until the data is already in hand and the clock is running. For public companies, Reg FD and material non-public information rules mean the drafting, legal review, and disclosure timing has to be locked before topline data arrives, not after. Scrambling under those constraints during a live readout is how companies say the wrong thing to the wrong audience at the worst possible moment.
Long Non-Revenue Periods Have No Communication Cadence
A biotech company can go three, five, seven years without meaningful revenue while burning cash on trials. Without a deliberate update rhythm between milestones, investors fill the silence with their own assumptions, usually worse than reality. Boards and shareholders need to hear something concrete on a set schedule, tied to actual clinical and regulatory progress, or confidence erodes quietly until a single bad update triggers an outsized reaction.
Setbacks Get Announced Poorly or Not at All
A failed trial or a Complete Response Letter from the FDA is not the end of a company, but it is often communicated like one, either buried in vague language or over-explained into a panic. Companies either go silent and let speculation fill the gap, or they overcorrect with defensive messaging that reads as spin to an audience trained to spot it. Neither approach protects the next round or the next readout.
Board Reporting Doesn't Connect Burn Rate to Milestones
Boards get a cash balance and a burn rate, presented separately from the clinical timeline that determines whether that cash gets the company to the next value-inflection event. When runway and milestones are reported as two disconnected numbers, boards can't make the tradeoff decisions they're actually there to make, and management loses credibility when a financing need arrives as a surprise.
One Message Doesn't Work Across a Split Investor Base
Specialist life sciences VCs and public biotech analysts read a clinical update differently than a generalist growth investor does. They want endpoint definitions, statistical power, and mechanism detail, not adjectives. Companies that write one investor update for everyone either lose the specialists with oversimplified language or lose the generalists with a document only a PhD can parse.
How We Help
We start with an audit, not a template. We read your last two years of investor updates, board decks, and any prior trial disclosures, and we map them against your actual clinical and regulatory calendar. Most of the time the gap is obvious within the first week: no readout playbook, no setback protocol, and a board report that lists cash and clinical progress as if they're unrelated.
From the audit we build the investor communication architecture your stage actually requires. For a Series A or B private company that means a disciplined update cadence and board reporting that ties burn rate directly to milestone timing. For a public or soon-to-be-public company, it means Reg FD-compliant disclosure workflows built with your legal counsel, drafted before data arrives, not after.
We write the readout playbooks in both directions. Every material trial gets a positive-outcome communication and a negative or ambiguous-outcome communication drafted in advance, reviewed by your scientific and legal teams, and ready to move the moment topline data locks. This is the single highest-leverage piece of work we do, because it removes the improvisation from the moment your company is most exposed.
We also build the setback protocol before you need it: how a trial failure or a Complete Response Letter gets communicated to preserve investor confidence in the underlying science and the team, without either minimizing the outcome or catastrophizing it. That protocol gets built once and reused, so the second setback (there is often a second) doesn't require rebuilding the wheel under pressure.
Execution includes conference-cycle preparation for JPM Healthcare Conference and the relevant scientific congresses for your indication, where a large share of your specialist investor meetings happen in a compressed window. We build the briefing materials, the Q&A prep for likely data-interpretation questions, and the segmented messaging that speaks to specialist life sciences investors and generalist analysts without diluting either.
What separates this from a standard IR retainer is that we are operators, not a communications vendor bolted onto your existing team. We work inside your cadence, alongside your CFO, general counsel, and scientific leadership, and we measure success by whether your investor base stays aligned through the non-revenue years, not by press release volume.
Measurement is straightforward: did the update cadence hold, did the readout playbook get used as written, and did board reporting actually change a financing or timeline decision. We track those, not vanity engagement metrics.
What we deliver
- Clinical trial readout communication playbooks, drafted for positive, negative, and ambiguous outcomes before data locks
- Reg FD-compliant disclosure workflow built jointly with legal counsel for material non-public information
- Board reporting format that ties burn rate and cash runway directly to clinical and regulatory milestones
- Pipeline setback communication protocol for trial failures and FDA Complete Response Letters
- Investor update cadence design for non-revenue periods (monthly or quarterly, tied to actual progress)
- JPM Healthcare Conference and scientific congress investor briefing materials and Q&A preparation
- Segmented messaging for specialist life sciences VCs versus public biotech analysts versus generalist investors
- Pre-release message review process with scientific and medical leadership before external distribution
A negative trial readout communicated badly doesn't cost you this quarter, it costs you the next financing round.
Our Methodology
We run this as a 90-day sprint, because biotech investor communication problems are usually structural, not creative, and structural problems get fixed on a defined timeline. Days 1 through 30 are the assessment: we review your investor communication history, map your clinical and regulatory calendar against your current disclosure practices, and interview your CFO, general counsel, and scientific leadership to find where the last update failed to land or where the next one is exposed.
Days 31 through 60 are build. We draft the readout playbooks for your next material catalyst in both directions, build the board reporting format that connects runway to milestones, and design the update cadence appropriate to your stage and investor base. If a scientific congress or JPM falls inside the sprint window, briefing materials get built here too.
Days 61 through 90 are execution and calibration against a live event, whether that's a board meeting, a conference, or an actual readout. We sit in on delivery, adjust the playbook based on what real investor questions surface, and hand you a system your team can run without us for the next cycle. If you want continued support past day 90, we move to a lighter retainer cadence built around your remaining catalyst calendar.
How We Work
The first 30 days are diagnostic and fast: we need your investor deck history, board materials, and clinical timeline in the first week to find the gaps before we propose fixes. Weeks 4 through 8 are heads-down build time on the specific playbooks and reporting formats your stage requires, with weekly checkpoints so nothing gets built in a vacuum.
Team structure is deliberately small. You work with a senior fractional lead who has run investor communications through actual trial readouts and disclosure events, not an account team. For engagements involving public-company disclosure, we work directly alongside your existing general counsel and CFO rather than trying to replace their function.
Cadence after the 90-day sprint is typically monthly, timed to your board meeting schedule and upcoming catalysts, not a fixed retainer clock that ignores your actual calendar. If your next readout or FDA decision falls in month four, we're back in the room for that specific event rather than waiting for a standing check-in.
If your biotech or pharma company needs investor communications support, we should talk.
- Investor confidence maintained through negative or ambiguous trial data releases
- Board reporting that connects burn rate and runway directly to milestone timing
- Consistent, predictable update cadence through multi-year non-revenue periods
- Reduced ad hoc scrambling during unplanned disclosure or setback events
- Distinct, accurate messaging for specialist life sciences investors versus generalist audiences
- Prepared, rehearsed investor meetings at JPM Healthcare Conference and major scientific congresses
If your biotech & pharma company needs investor & stakeholder communications leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How do you handle Reg FD compliance when drafting investor communications for public biotech companies?
We don't replace your legal counsel, we build the disclosure workflow alongside them. Every readout playbook and material update goes through the same legal review process your company already uses for material non-public information, we just make sure the drafts exist and are reviewed before the data arrives instead of after.
What if our trial readout is negative – how do you communicate that without triggering an investor panic?
The negative-outcome version gets drafted and reviewed at the same time as the positive one, before you know which one you need. It states the result plainly, explains what it does and doesn't mean for the broader pipeline and cash position, and avoids both defensive over-explanation and vague language that reads as evasive.
Do you work with our existing IR firm or general counsel, or do you replace them?
We work alongside them. Your general counsel owns legal sign-off on any material disclosure, and if you have an IR firm handling shareholder logistics, we coordinate with them on message content rather than duplicating their function.
How is investor communication different for a public biotech versus a private Series B company?
Public companies operate under Reg FD and material non-public information rules that dictate timing and disclosure format for any market-moving update, including trial data. Private Series A and B companies have more flexibility on timing but face a different problem: a smaller, more concentrated investor base where losing confidence with two or three lead investors can end a financing relationship.
What is your approach to board reporting on burn rate and runway?
We build a reporting format that shows cash runway next to the specific clinical or regulatory milestone it needs to reach, not as two separate line items. This lets the board see directly whether the company reaches its next value-inflection event before it needs to raise again, which is the actual decision a board needs to make.
Can you help us prepare for JPM Healthcare Conference or scientific congress investor meetings?
Yes. We build the briefing materials and rehearse likely questions from specialist life sciences investors and public biotech analysts, who tend to probe endpoint definitions, statistical power, and mechanism detail rather than accept summary claims.
